BeiGene, Ltd. (BGNE)
After hours:
| Previous Close | 152.71 |
| Open | 152.78 |
| Bid | 152.57 x 100 |
| Ask | 153.33 x 100 |
| Day's Range | 151.45 - 154.39 |
| 52 Week Range | 126.97 - 229.57 |
| Volume | |
| Avg. Volume | 188,667 |
| Market Cap | 17.367B |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.56 |
| Earnings Date | Jul 31, 2024 - Aug 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 268.16 |
GlobeNewswireBriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS™ First in Human Study
Study to evaluate the effects of Bria-OTS™ in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces a clinical supply agreement with BeiGene, Ltd. (NASD
Business WireBRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
SAN MATEO, Calif., May 24, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of new analyses for BRUKINSA® (zanubrutinib) at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31 - June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton’s tyrosine kinase inhibitors (BTKis) used to treat chronic lymphocytic leukemia (CLL) and small lymphoc
ZacksBeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
